DDInter41 DDInter255
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) upregulates {v} (Gene) C5
C5 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimetrexate
Trimetrexate {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Hyponatraemia {u} (Side Effect) is caused by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbamazepine
Carbamazepine {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Imatinib {u} (Compound) binds {v} (Gene) ABL1
ABL1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Irinotecan {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) upregulates {v} (Gene) STX1A
STX1A {u} (Gene) is downregulated by {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Altretamine
Altretamine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Busulfan
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Methylprednisolone {u} (Compound) palliates {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) upregulates C5 (Gene) and C5 (Gene) is upregulated by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate and Trimetrexate (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib (Compound) binds ABL1 (Gene) and ABL1 (Gene) is upregulated by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is upregulated by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) upregulates STX1A (Gene) and STX1A (Gene) is downregulated by Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Busulfan (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)